Your browser doesn't support javascript.
loading
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.
Jackisch, C; Kim, S-B; Semiglazov, V; Melichar, B; Pivot, X; Hillenbach, C; Stroyakovskiy, D; Lum, B L; Elliott, R; Weber, H A; Ismael, G.
Afiliação
  • Jackisch C; Department of Obstetrics and Gynecology and Breast Cancer and Gynecology Cancer Center, Sana Klinikum Offenbach GmbH, Offenbach, Germany christian.jackisch@sana.de.
  • Kim SB; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Semiglazov V; Department of Surgery, NN Petrov Research Institute of Oncology, St Petersburg, Russia.
  • Melichar B; Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
  • Pivot X; Chemotherapy-Oncology, CHU Jean Minjoz, Besançon, France.
  • Hillenbach C; Department of Biopharmaceuticals, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Stroyakovskiy D; Chemotherapeutic Department, City Clinical Oncology Hospital 62, Moscow, Russia.
  • Lum BL; Clinical Pharmacology.
  • Elliott R; BioAnalytical Sciences, Genentech, South San Francisco, USA.
  • Weber HA; Department of Biopharmaceuticals, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Ismael G; Hospital Amaral Carvalho, Jaú, Brazil.
Ann Oncol ; 26(2): 320-5, 2015 Feb.
Article em En | MEDLINE | ID: mdl-25403587
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Trastuzumab / Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Trastuzumab / Antineoplásicos Idioma: En Ano de publicação: 2015 Tipo de documento: Article